کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3331866 | 1590871 | 2007 | 41 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Management of Relapsed and Relapsed Refractory Myeloma
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
هماتولوژی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Studies of bortezomib, thalidomide, and lenalidomide have shown promising clinical activity in relapsed/refractory multiple myeloma (MM). Bortezomib alone and in combination with other agents is associated with high response rates, consistently high rates of complete response, and a predictable and manageable profile of adverse events. Thalidomide-based regimens have also shown substantial clinical activity. The accumulating experience from ongoing trials of bortezomib/lenalidomide/dexamethasone combinations in patients who have relapsed/refractory or newly diagnosed MM will provide critical information that will determine the possible role of this combination as the basic backbone for combination regimens for management of advanced MM.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Hematology/Oncology Clinics of North America - Volume 21, Issue 6, December 2007, Pages 1175–1215
Journal: Hematology/Oncology Clinics of North America - Volume 21, Issue 6, December 2007, Pages 1175–1215
نویسندگان
Efstathios Kastritis, Constantine S. Mitsiades, Meletios A. Dimopoulos, Paul G. Richardson,